Gyre Therapeutics is trading at $6.51, down 5.79%, as post-earnings concerns continue to pressure shares.
- Its August 7 quarterly loss missed analyst expectations by $0.06 per share, although revenue exceeded estimates.
- Zacks Research downgraded the company from hold to strong sell on August 20, 2026, likely reinforcing bearish sentiment into August 24.
- Broader markets are only moderately mixed, making company-specific concerns more relevant.